Category: Cardiac Implants
Medtech titan Medtronic enrolls the 1st patients in the AdaptResponse clinical trial to evaluate its adaptive cardiac rhythm management technology.
Medtronic (NYSE:MDT) touted the launch of its AdaptResponse trial, the largest study of its kind evaluating the company's AdaptivCRT algorithm for personalizing cardiac resynchronization therapy in treatment of heart failure.
An FDA advisory panel is slated to convene yet again in October to consider the safety and efficacy of Boston Scientific's Watchman anti-stroke heart repair device.
Occlutech says a U.K. court invalidated a patent held by St. Jude Medical covering atrial septal occluder technology.
An new study shows that transcatheter aortic valve-in-valve implantation may be an important option for a growing population of patients with deteriorating bioprosthetic implants, but outcomes depend strongly on how the previous valve is failed.
New research released this week provides more support for the use of transcatheter aortic valve-in-valve (VIV) implantation as a means of replacing previously implanted valves that have deteriorated over time.
Abbott's MitraClip implant reduces mitral regurgitation and improves quality of life at 1 year in high-risk patients, according to new study results from the Everest II clinical trial.
High-risk patients with mitral regurgitation reduced their symptoms and reported better quality of life after treatment with Abbott's (NYSE:ABT) MitraClip implant, according to newly published results from the Everest II High Risk Registry.
Massachusetts-based DC Devices closed a $34 million Series D funding round in supports of its transcatheter InterAtrial Shunt Device.
Bay State startup DC Device announced the successful close of a $34 million Series D financing round, hoping to use the funds to advance clinical evaluation of its InterAtrial Shunt Device.
The company aims to market the world's 1st minimally invasive device for treating diastolic heart failure, a market worth a potential $5 billion globally, according to a DC Device press release.
Medtech titan Boston Scientific finally unveils the full results from its PREVAIL study, which was the subject of controversy at last year's ACC conference.
Boston Scientific (NYSE:BSX) this week unveiled full results from the PREVAIL clinical trial of the Watchman anti-stroke implant, largely agreeing with earlier reports that the device missed a co-primary endpoint for efficacy.